TPLC treats premarket review, post-market surveillance, manufacturing controls, and software updates as a connected continuum rather than discrete events. The TPLC database links 510(k), PMA, recall, MDR, and inspection data per device type. FDA's CDRH organizes its review offices around the TPLC approach, so the same teams look at premarket submissions and post-market signals for a device type. For software and AI, TPLC thinking means planning for updates, monitoring real-world performance and managing cybersecurity throughout the product's life, not just at clearance. The public TPLC database is a useful starting point for researching a device type's history.

Why it matters

Especially central to AI/ML devices, where post-market performance monitoring and PCCP-driven updates are part of the regulatory lifecycle.

Common pitfalls

•A common pitfall is treating premarket approval as the end of regulatory oversight, rather than an ongoing process, especially for rapidly evolving technologies like AI/ML. Another mistake is failing to integrate post-market surveillance data effectively into product development and risk management processes. Companies often underestimate the resources required for continuous monitoring and updates throughout the product's entire lifecycle.
•Overlooking the need for a robust change management process for software updates can lead to regulatory non-compliance.
•Failing to maintain traceability between software versions, risk assessments, and clinical performance data is a significant pitfall.

Sources

TPLC Database · FDA
MDCG Software Guidance · MDCG
FDA - Software as a Medical Device (SaMD) · FDA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.